Biotech is alive and kicking!.

In the global crisis, Biotech is still alive. Numerous news are giving hints that some thawing is occurring in this never-ending postnuclear winter that the debt crisis brought to Europe nobody remembers how long ago… So the best way to get these inputs is to keep moving… Alive and kicking!.

Thus, our CSO, Dr. Maes flys this week-end to San Diego to present Oryzon’s Epigenetic advances at the 4th Annual CHI X-Gen Congress, in the CLINICAL GENOMICS. Epigenetics, Targets and Therapies: on March 5-7 March at the Hilton San Diego Resort in San Diego, California. Tamara's presentation will occur on March 6th at 11:00 am. Under the title “Development of Novel, Potent LSD1 Inhibitors and Their In Vitro and In Vivo Effects on Tumor Cell Growth”.

The TARGET AND THERAPIES session will be chaired by Dr Andrew Pope, Group Director of the Technology & Science Platform of GlaxoSmithKline who will give an Overview of Current and Developing Approaches to The Discovery of New Chemical Matter which Modulates Epigenetic Targets. In the same session, the Directors of Biology of Epizyme and Constellation Pharmaceuticals, two other companies active in the Epigenetic field, together with researchers from the Harvard Medical School will also present other interesting aspects of the field.

Epigenetics is a very, very hot spot field in the pharmaceutical industry. It is predicted that world revenues for epigenetic therapies and technologies will reach $2.73bn in 2015 and that the overall market will grow with a CAGR of 16% between 2010 and 2015. Therapies will remain the largest source of revenue in the epigenetics market. The deal activity on the field is intense. Constellation's deal with Genentech last january and Epizyme's one with GSK prove it.

And in three weeks from now we will be also in Amsterdam in the Bio- Europe Spring Conference, with about 2000 delegates from more than 1000 firms. Oryzon’s is having a loaded program with international companies and investors.